PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), today announced financial results for its fiscal 2017 second quarter ended March 31, 2017. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.
Conference Call and Webcast Details
Investors may access a live audio webcast on the Company’s website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 12326590.
A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and enter Conference ID 12326590.
Selected Fiscal 2017 Second Quarter and Recent Events
- Presented clinical data on former drug candidates ARC-520, ARC-521, and ARC-AAT at the EASL International Liver Congress with data that included the following findings:
- Multiple-dose treatment with ARC-520 in combination with entecavir led to:
- Reductions in hepatitis B surface antigen, or HBsAg, of up to 3.1 logs with a mean maximum reduction of 2.2 logs
- Reductions in HBV DNA of several logs and to an undetectable level in many patients
- ARC-521 appeared active against HBV gene products derived from both cccDNA and integrated HBV DNA
- ARC-AAT treatment led to deep, durable and dose-dependent reductions of serum AAT with similar levels of knockdown observed in healthy volunteers and patients
- Multiple-dose treatment with ARC-520 in combination with entecavir led to:
- Continued progress on preclinical pipeline including ARO-HBV, ARO-AAT, ARO-F12, ARO-HIF2 and additional programs against undisclosed targets
- Continued progress on cardiovascular disease collaboration with Amgen, which includes ARO-LPA and ARO-AMG1
- Made key advancements in platform technology development including:
- A proprietary subcutaneously administered, liver-targeted delivery vehicle
- An extra-hepatic delivery platform, which includes multiple designs and structures depending on the type of extra-hepatic tissue that is being targeted
Selected Fiscal 2017 Second Quarter Financial Results
